Analysis published 30 Jun 2026
AI-generated · cited to primary sources · not investment advice
Johnson & Johnson Common Stock (JNJ) Sep 2025 Filing Analysis
01 · Management Credibility
Does management do what it says?
MetPharmaceuticals Margin Profile
68/100
The program is active with $157 million in costs recorded year-to-date in 2025 against the $0.9-$1.0 billion target. (2 in progress, 1 met across 3 tracked commitments)
“The estimated costs of the total program are between $0.7 billion - $0.8 billion and will be substantially completed by the end of fiscal year 2025.”
Johnson & Johnson Common Stock · QUARTERLY_REPORT · Sep 2025 · p.74
See the full cited Management analysis of Johnson & Johnson Common Stock
Keep Reading
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.